Introduction
============

The aim of this retrospective study is to evaluate hemodynamic and neurohormonal effects of levosimendan in cardiac patients with sepsis-induced cardiac dysfunction. Septic shock is characterized by profound cardiovascular alterations including myocardial depression. Levosimendan has recently been shown to improve cardiac function in septic shock.

Methods
=======

Fifteen patients with myocardial depression related to septic shock were enrolled. All patients had SIRS criteria, culture isolation of one or more pathogens, positive procalcitonin, SBP \< 90 mmHg unresponsive to load challenge. We defined myocardial depression as a reduced SvO~2~in the presence of increased brain natriuretic peptide secretion and Troponin I release, and systolic and/or diastolic dysfunction by transoesophageal echo evaluation of ejection fraction and mitral annulus tissue Doppler imaging velocities. All patients received levosimendan infusion for 24 hours at 0.1 μg/kg/min combined with norepinephrine.

Results
=======

Data were obtained by evaluating the average of the percentage variation between T~0~(starting infusion) and T~1~(24 hours after infusion), T~2~(48 hours), T~3~(72 hours), T~4~(96 hours), T~5~(120 hours) and T~6~(144 hours). Levosimendan significantly increased SvO~2~and ejection fraction, and decreased Troponin I and brain natriuretic peptide. Levosimendan improved diastolic function by increasing the *E*\' velocity at tissue Doppler imaging at 48 hours. All data were analysed by the Fisher *F*test.

Conclusion
==========

Levosimendan seems to improve systemic hemodynamics and neurohormonal cardiac function in patients with septic cardiac dysfunction.

                   T~0~   T~1~   T~2~   T~3~   T~4~   T~5~   T~6~
  ---------------- ------ ------ ------ ------ ------ ------ ------
  SvO~2~(%)        0      4      10     17     22     19     22
  Trop I (ng/ml)   0      -65    -86    -82    -78    -62    -62
  BNP (%)          0      -45    -41    -56    -50    -42    -44
  *E*\' (cm/s)     \<8    \>8    \>8    \>8    \>8    \>8    \>8
  EF (%)           \<30   \>40   \>40   \>40   \>40   \>40   \>40
